Go Pro
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
$20.59
-2.0%		$19.46
$5.68
▼
$23.19
$1.33B0.02673,468 shs1.09 million shs
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
$1.94
$2.10
$0.44
▼
$3.04
$351.29M1.59380,130 shs465,714 shs
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
$24.60
-0.9%		$28.20
$22.01
▼
$53.65
$1.37B2.17390,577 shs1.05 million shs
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$14.30
-0.7%		$25.96
$13.81
▼
$39.89
$1.41B0.314.35 million shs3.25 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
0.00%-6.79%+4.84%+50.29%+218.24%
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
0.00%-8.06%+0.52%-13.78%+282.12%
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
0.00%-6.14%-11.10%+2.29%+53.56%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
0.00%-6.54%-45.79%-41.27%-54.30%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
$20.59
-2.0%		$19.46
$5.68
▼
$23.19
$1.33B0.02673,468 shs1.09 million shs
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
$1.94
$2.10
$0.44
▼
$3.04
$351.29M1.59380,130 shs465,714 shs
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
$24.60
-0.9%		$28.20
$22.01
▼
$53.65
$1.37B2.17390,577 shs1.05 million shs
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$14.30
-0.7%		$25.96
$13.81
▼
$39.89
$1.41B0.314.35 million shs3.25 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
0.00%-6.79%+4.84%+50.29%+218.24%
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
0.00%-8.06%+0.52%-13.78%+282.12%
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
0.00%-6.14%-11.10%+2.29%+53.56%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
0.00%-6.54%-45.79%-41.27%-54.30%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
2.78
Moderate Buy$32.8659.58% Upside
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
2.43
Hold$4.75144.85% Upside
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
3.08
Buy$66.00168.29% Upside
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
2.52
Moderate Buy$36.63156.16% Upside

Current Analyst Ratings Breakdown

Latest IPSC, MAZE, RARE, and CGEM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/4/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$28.00 ➝ $19.00
9/4/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$43.00 ➝ $32.00
9/3/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeModerate Buy ➝ Hold
9/3/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$77.00 ➝ $28.00
9/3/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$58.00 ➝ $28.00
9/3/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$49.00 ➝ $18.00
9/3/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Neutral
9/3/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$30.00 ➝ $23.00
9/3/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$83.00 ➝ $37.00
9/3/2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
8/24/2026
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/A$6.92 per shareN/A
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
$109.16M3.22$0.01 per share145.86$1.82 per share1.07
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
$167.50M8.16N/AN/A$7.38 per share3.33
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
$673M2.09N/AN/A($0.83) per share-17.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$219.88M-$3.10N/AN/AN/AN/A-52.89%-48.18%11/5/2026 (Estimated)
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
-$9.58M-$0.93N/AN/AN/AN/A-49.51%-38.09%11/12/2026 (Estimated)
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
-$131.12M-$2.52N/AN/AN/AN/A-34.94%-30.18%N/A
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-$575M-$5.84N/AN/AN/A-81.79%-1,024.42%-44.40%11/3/2026 (Estimated)

Latest IPSC, MAZE, RARE, and CGEM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
-$0.11-$0.17-$0.06-$0.17$2.17 millionN/A
8/11/2026Q2 2026
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
-$0.76-$0.76N/A-$0.76N/AN/A
8/6/2026Q2 2026
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
-$0.7993-$0.81-$0.0107-$0.81$3.67 millionN/A
8/4/2026Q2 2026
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
-$1.22-$0.90+$0.32-$0.90$183.08 million$214.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/AN/AN/AN/AN/A
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
N/AN/AN/AN/AN/A
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
N/AN/AN/AN/AN/A
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
N/A
8.42
8.42
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
N/A
8.28
8.28
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
0.09
18.31
18.31
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
N/A
1.73
1.56

Institutional Ownership

CompanyInstitutional Ownership
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
86.31%
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
50.20%
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
N/A
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
97.67%

Insider Ownership

CompanyInsider Ownership
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
8.60%
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
2.40%
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
5.30%
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
5.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cullinan Therapeutics, Inc. stock logo
CGEM
Cullinan Therapeutics
10964.36 million58.82 millionOptionable
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
170181.07 million176.73 millionOptionable
Maze Therapeutics, Inc. stock logo
MAZE
Maze Therapeutics
14155.55 million52.61 millionN/A
Ultragenyx Pharmaceutical Inc. stock logo
RARE
Ultragenyx Pharmaceutical
1,37198.59 million93.46 millionOptionable

Recent News About These Companies

Squarepoint Ops LLC Sells 106,171 Shares of Ultragenyx Pharmaceutical Inc. $RARE
September 10 at 5:27 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-squarepoint-ops-llc-sells-106171-shares-of-ultragenyx-pharmaceutical-inc-rare-2026-09-10/
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3358203/1087/en/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-ultragenyx-pharmaceutical-inc-rare.html
Goldman Sachs Reaffirms Their Hold Rating on Ultragenyx Pharmaceutical (RARE)
September 7, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RARE/pressreleases/4459694/goldman-sachs-reaffirms-their-hold-rating-on-ultragenyx-pharmaceutical-rare/
Barclays Remains a Buy on Ultragenyx Pharmaceutical (RARE)
September 7, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RARE/pressreleases/4459164/barclays-remains-a-buy-on-ultragenyx-pharmaceutical-rare/
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives $59.44 Consensus PT from Analysts
September 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31006801
Barclays Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price
September 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31006001
Ultragenyx Pharmaceutical (NASDAQ:RARE) Cut to "Hold" at Royal Bank Of Canada
September 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31006006
The Goldman Sachs Group Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $19.00
September 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31005897
Citigroup Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $28.00
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31005390
HC Wainwright Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $25.00
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31005389
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Lowered by Wells Fargo & Company
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31005388
TD Cowen Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31005387
Evercore Downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) to In-Line
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31005383
Ultragenyx Pharmaceutical (NASDAQ:RARE) Rating Lowered to Neutral at Robert W. Baird
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31005384
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Lowered by JPMorgan Chase & Co.
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31005381
Cantor Fitzgerald Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $33.00
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31004278
Jefferies Financial Group Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31004284
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Lowered by Bank of America
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31004268
Ultragenyx Pharmaceutical (NASDAQ:RARE) Rating Lowered to Market Perform at William Blair
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31004274
Canaccord Genuity Group Has Lowered Expectations for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31004276
Wedbush Lowers Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $23.00
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31004275

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
Illustration of a computer chip on a circuit board with an upward green stock chart line in a server room.
Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
By Thomas Hughes | August 31, 2026
Shoppers browse folded and hanging clothing in a retail apparel store with shelves and racks displayed.
3 Retail Stocks to Watch After a Big Consumer Earnings Week
By Dan Schmidt | August 29, 2026
Composite image showing rare earth ore mining, processed metal materials in a factory, and nuclear power plant cooling towers.
3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
By Chris Markoch | September 10, 2026
Cullinan Therapeutics stock logo

Cullinan Therapeutics NASDAQ:CGEM

$20.59 -0.41 (-1.95%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$21.53 +0.94 (+4.58%)
As of 09/11/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Century Therapeutics stock logo

Century Therapeutics NASDAQ:IPSC

$1.94 0.00 (0.00%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$1.92 -0.01 (-0.77%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Maze Therapeutics stock logo

Maze Therapeutics NASDAQ:MAZE

$24.60 -0.22 (-0.89%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$24.65 +0.05 (+0.20%)
As of 09/11/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. Our goal is to bring novel precision medicines to patients to maximize our impact on human health. CKD is a serious, progressive condition that affects approximately 37 million patients in the United States, where it is expected to be the fifth most prevalent chronic disease by 2040. Current treatments for CKD consider patients as falling into clinical categories and focus on slowing the progression of disease, but do not target the underlying genetic drivers of disease. Our lead programs are designed to phenocopy, or mimic, the protective effects of certain genetic variants that are associated with reduced disease burden and improved kidney function in distinct groups of CKD patients. Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD, which is estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal dysfunction has been known for over a decade, we have identified a new protective variant that underpins our therapeutic approach for MZE829 and may ultimately allow us to address a broader population of AKD than has previously been possible in the clinical setting. In October 2024, we reported results for our Phase 1 clinical trial of MZE829, in which we enrolled 111 healthy patients who received either single or multiple ascending doses of 20 mg to 480 mg of MZE829 administered daily. Treatment was well tolerated with no severe adverse events or serious adverse events reported in patients treated with single doses up to 480 mg and multiple doses of up to 350 mg daily for seven days. Dose-proportional pharmacokinetics, or PK, was observed with low variability (10-40%) across doses. We initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose our first patient in the first quarter of 2025 and to report proof of concept data in the first quarter of 2026. Our second lead program, MZE782, is an oral, small molecule inhibitor of the solute transporter SLC6A19, a novel CKD target, with the potential to address approximately five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today’s standard of care. We initiated a Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025. In addition to CKD, we believe MZE782 may provide benefit to patients suffering from the genetically defined metabolic disease, phenylketonuria, or PKU. Following our ongoing Phase 1 trial of MZE782, we plan to conduct a parallel Phase 2 clinical trial to explore MZE782 as a potential treatment of PKU. Our Compass platform supports end-to-end variant identification and functionalization capabilities as well as advanced research tools and methodologies for drug development. We believe the process of variant functionalization, or understanding how genetic variants function to affect the course of disease, is a foundational aspect of precision medicine and one of the core capabilities that sets us apart from others in the field. We were incorporated under the laws of the State of Delaware on August 29, 2017, originally under the name Genetic Modifiers NewCo, Inc. We changed our name on July 5, 2018 to Modulus Therapeutics, Inc. and on September 25, 2018, to Maze Therapeutics, Inc. Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California.

Ultragenyx Pharmaceutical stock logo

Ultragenyx Pharmaceutical NASDAQ:RARE

$14.30 -0.10 (-0.69%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$14.30 0.00 (-0.01%)
As of 09/11/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas